NSE vs BSE: Turf war over derivatives market heats up

A rivalry between India's major stock exchanges has entered a high-stakes phase, as they wrestle for control over the derivatives market in potential implications for everything from trading volumes to liquidity flows.
ADVERTISEMENT The National Stock Exchange of India Ltd. is trying to change the expiration for listed derivative contracts from Thursday to Tuesday — a day traditionally dominated by its smaller bourse BSE Ltd. A shift could help the NSE regain market share from its rival, which has benefited after curbs by the capital markets regulator hit trading of NSE's most-popular options, pushing traders to look for alternatives at the BSE.
The expiry-day wrangling is more than just a turf war. It can potentially reshape India's options trading by fragmenting liquidity, influencing fee income and forcing brokers to realign their trade execution strategies. For the NSE, retaining its competitive edge becomes crucial ahead of a long-anticipated listing.
'It will only get more competitive from here,' said Maurya Ghelani, derivatives strategist at Kai Securities in Mumbai. 'A lot depends on how the BSE responds, and it may have to contend with ceding some ground back to the NSE.'Derivatives trading accounts for a significant chunk of revenue for both exchanges, with India attracting global quantitative trading firms like Citadel and Jane Street. The NSE has seen a steady decline in its market share in the past year as the securities regulator culled highly traded weekly contracts such as the ones on the NSE Nifty Bank Index, prompting a shift toward options on the S&P BSE Sensex Index.Since the Securities and Exchange Board of India began its latest curbs to halt the derivatives frenzy, the NSE has struggled to stick to an expiration day. In November, it said it would move it to Thursday for several index derivatives, following BSE's streamlining of its expiries to Tuesday.
ADVERTISEMENT Then in March, the NSE unexpectedly said it would change its expiration day to Monday, putting it ahead of the BSE's. The move was quickly abandoned as the regulator pushed the exchanges to stick to either Tuesday or Thursday. The news of a new push for a change to Tuesday came last week. The BSE hasn't said whether it will stick to Tuesday or consider moving its expiration to Thursday. The Sebi, which says it aims to protect investor interests and maintain market stability, has yet to announce its decision on the NSE's request to move its expiry day. For his part, NSE Chief Executive Officer Ashish Kumar Chauhan told analysts in its latest earnings call that the market share loss has 'run its course.'
ADVERTISEMENT Ghelani of Kai Securities said aligning expiry days could lead to new product launches by exchanges and deeper integration among existing ones. Meanwhile, the National Commodity and Derivatives Exchange Ltd. is also planning to enter the fray. While intensified competition may lead to short-term volatility and fragmentation, some say the derivatives market may benefit in the long run.
ADVERTISEMENT 'More options will bring more opportunities for the trader community,' said Sahaj Agrawal, head of derivatives research at Kotak Securities. 'This could spur innovation and better services for traders.'
(You can now subscribe to our ETMarkets WhatsApp channel)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

27 minutes ago

• Business Standard

Influx Healthtech IPO booked 200x; check allotment, GMP, listing date

Influx Healthtech IPO allotment status: The basis of allotment of shares for Influx Healthtech is expected to be finalised today, Monday, June 23, 2025. The initial public offering (IPO) of Influx Healthtech, which closed for subscription on Friday, June 20, received a robust response from investors, with the offering being over subscribed by over 201 times. Investors bid for 817.53 million equity shares, which was 201.4 times the public issue size of 4.05 million shares, through 220,338 applications. After the allotment process is completed, investors can verify their IPO allotment status by visiting the official websites of the National Stock Exchange (NSE) and Maashitla Securities, the designated registrar for the Influx Healthtech IPO. Alternatively, they can use the direct links provided below to check their allotment status online: Check Influx Healthtech IPO allotment status on NSE: Check Influx Healthtech IPO allotment status on Maashitla Securities: Influx Healthtech IPO grey market premium (GMP) The unlisted shares of Influx Healthtech were trading at ₹118 in the grey market, commanding a premium of ₹22 or 22.3 per cent compared to the upper price band of ₹96 per share, according to sources tracking unofficial markets. Influx Healthtech IPO details The Mumbai-based company aims to raise ₹58.57 crore through a combination of a fresh issue of 5 million equity shares and an offer for sale (OFS) of 1.1 million equity shares at a price band of ₹91-96 per share. Shares of Influx Healthtech are scheduled to be listed on the NSE SME platform on Wednesday, June 25. Rarever Financial Advisors is the sole book-running lead manager. According to the red herring prospectus (RHP), the company intends to use the net fresh issue proceeds for the set up of the manufacturing facility Nutraceutical Division, a manufacturing facility for the Veterinary Food Division; purchase of machinery for Homecare and Cosmetic Division, and general corporate purposes. About Influx Healthtech Incorporated in 2020, Mumbai-based Influx Healthtech is a healthcare-focused company specialising in contract manufacturing. It operates a manufacturing facility located in Thane, Maharashtra. The company produces Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, care products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.

Business Standard

27 minutes ago

• Business Standard

Vedanta, 2 others to trade ex-dividend on June 24; do you own any?

Dividend stocks: Shares of Vedanta, Polycab India, and Alkyl Amines Chemicals are set to remain in spotlight today, June 23, following their announcement of dividend rewards for their shareholders. These shares, BSE data suggest, will trade ex-dividend tomorrow, June 24. The ex-dividend date is when a stock starts trading without the right to receive the declared dividend. To be eligible, investors must own the stock before this date. Companies determine the list of eligible shareholders based on their records on the record date. Vedanta dividend 2025 Metal and mining major Vedanta informed the exchanges that its board of directors has considered and approved the first interim dividend of ₹7 per equity share on face value of ₹1 per equity share for the Financial Year 2025-26, amounting to ₹2,737 crore. The record date for the purpose of payment of dividend, Vedanta said, shall be Tuesday, June 24, 2025, and the interim dividend shall be duly paid within the stipulated timelines as prescribed under law. Polycab India dividend 2025 Wires and cables manufacturer Polycab India 's board has recommended a dividend @ 350 per cent i.e. ₹35 per equity share of face value of ₹10 each for the Financial Year 2024-25, subject to approval of members at the ensuing Annual General Meeting. "The dividend, if approved by the members in the ensuing Annual General Meeting, will be paid on or before 30 days from the date of the Annual General Meeting," said the company in an exchange filing. Alkyl Amines Chemicals dividend 2025 Specialty chemicals manufacturer Alkyl Amines Chemicals has informed the exchanges that its board has recommended a final dividend of ₹10 per equity share of ₹2 each (i.e., 500 per cent) for the Financial Year (F.Y.) 2024-25. The dividend is, however, subject to approval by the shareholders at the ensuing Annual General Meeting. Alkyl Amines Chemicals has fixed Tuesday, June 24, 2025, as the 'record date' for determining entitlement of members to dividend for the financial year ended March 31, 2025, if approved at the AGM.

Business Standard

27 minutes ago

• Business Standard

Arisinfra Solutions IPO allotment today; check status, GMP, listing date

Arisinfra Solutions IPO allotment status: The basis of allotment for the Arisinfra Solutions IPO shares is likely to be finalised today, Monday, June 23, 2025. The public offering closed for subscription on Friday, June 20, 2025, receiving decent participation from investors and getting oversubscribed by 2.65 times. Here's how to check Arisinfra Solutions IPO online Once the Arisinfra Solutions IPO allotment is finalised, investors can check their status on the official websites of BSE, NSE, or MUFG Intime India (erstwhile Link Intime), the registrar for the issue. Alternatively, investors can use these direct links to check the Arisinfra Solutions IPO allotment status directly: Arisinfra Solutions IPO final subscription status The ₹499.60 crore public offering of Arisinfra Solutions, offered at a price band of ₹210–222 with a lot size of 67 shares, received bids for 3,46,72,835 shares against the 1,30,84,656 shares offered. This led to an oversubscription of 2.65 times by the end of the subscription period, according to data available on the BSE. Arisinfra Solutions IPO witnessed the highest participation from the retail investors who subscribed to 5.59 times the portion reserved for them, non-institutional investors (NIIs) at 3.14 times, and qualified institutional buyers (QIBs) at 1.42 times. Arisinfra Solutions IPO grey market premium (GMP) today According to sources tracking unofficial market activities, the unlisted shares of Arisinfra Solutions were seen trading flat at ₹222 per share. Thus, the grey market premium (GMP) for Arisinfra Solutions IPO remains nil on Monday. Arisinfra Solutions IPO likely listing price Shares of Arisinfra Solutions are scheduled to list on the BSE and NSE on Wednesday, June 25, 2025. The current grey market trends indicate a flat listing of Arisinfra Solutions shares. However, these estimates may vary, as the grey market is unregulated, and GMP should not be considered a reliable indicator of performance. About Arisinfra Solutions Incorporated in 2021, Arisinfra Solutions is a B2B technology-driven platform that simplifies procurement processes for construction and infrastructure companies. The company delivers a range of construction materials, including steel, cement, and aggregates. The company's product portfolio includes GI pipes, MS wire, and OPC bulk cement. Arisinfra Solutions has a subsidiary, ArisUnitern Re Solutions Private, which provides value-added services to real estate developers.